Exenatide
First GLP-1 receptor agonist to reach market, derived from Gila monster venom protein exendin-4. Available as Byetta (twice daily) and Bydureon (weekly extended-release).
0 anonymous reports
Also known as:
byettabydureonexendin-4
browse topics:
community guides:
No reports found.
Community Q&A
- How does exenatide compare to semaglutide for weight loss?
- Community accounts consistently describe semaglutide as producing significantly greater weight loss than exenatide. Exenatide accounts come predominantly from people prescribed it before newer agents were available, or from those managing cost and access. Twice-daily injection for Byetta is consistently cited as a practical disadvantage versus once-weekly options. Accounts that remained on exenatide after semaglutide became available are almost always driven by insurance coverage or cost.
- What are the side effects of exenatide?
- Community accounts describe a GI profile similar to other GLP-1 agents — nausea, reduced appetite, and occasional vomiting — most pronounced in the first weeks. Injection site nodules appear more frequently in Bydureon accounts than with other GLP-1 formulations, attributed to the microsphere depot mechanism. Pancreatitis concerns circulate in the community; adverse events of this severity are rarely described in confessions but frequently flagged as a known risk.